Ampio Pharmaceuticals (NYSE:AMPE) Shares to Reverse Split on Tuesday, September 12th

Ampio Pharmaceuticals, Inc. (NYSE:AMPE)’s stock is set to reverse split before the market opens on Tuesday, September 12th. The 1-20 reverse split was announced on Thursday, August 31st. The number of shares owned by shareholders will be adjusted after the market closes on Monday, September 11th.

Ampio Pharmaceuticals Stock Up 2.1 %

Shares of Ampio Pharmaceuticals stock opened at $0.20 on Monday. The company has a 50 day moving average price of $0.24 and a 200 day moving average price of $0.25. Ampio Pharmaceuticals has a 52 week low of $0.17 and a 52 week high of $1.90.

Ampio Pharmaceuticals (NYSE:AMPE) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Ampio Pharmaceuticals in a report on Friday. They issued a “sell” rating on the stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Two Sigma Advisers LP raised its stake in shares of Ampio Pharmaceuticals by 304.3% in the 3rd quarter. Two Sigma Advisers LP now owns 432,216 shares of the company’s stock valued at $26,000 after purchasing an additional 325,300 shares during the period. HRT Financial LP increased its position in Ampio Pharmaceuticals by 1,399.2% during the first quarter. HRT Financial LP now owns 217,052 shares of the company’s stock worth $50,000 after buying an additional 202,574 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Ampio Pharmaceuticals by 73.5% during the second quarter. Price T Rowe Associates Inc. MD now owns 394,100 shares of the company’s stock worth $66,000 after buying an additional 166,979 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Ampio Pharmaceuticals during the second quarter worth approximately $72,000. Finally, Bank of Montreal Can bought a new stake in shares of Ampio Pharmaceuticals during the first quarter worth approximately $168,000.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis-related pain. It focuses on the preclinical development of AR-300, a novel proprietary, small molecule formulation for the treatment of osteoarthritis of the knee. The company is headquartered in Englewood, Colorado.